Ascendis Pharma AS (ASND) reports significant milestones and market traction, despite facing revenue and reimbursement hurdles.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

These ten new MoUs follow NUPCO’s recent agreements with global pharmaceutical leaders, including Novo Nordisk (Denmark) and ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Commenting on the Champions Initiative, Cradle co-founder and chief executive Stef van Grieken said that technological ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

The higher he climbs, the less he thinks about daily life, says Novo Nordisk’s Cem Ozenc. There’s no time when the mental and ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

European Opportunities Trust invests in European companies offering capital growth and is managed by Devon Equity Management Ltd. The company said net asset value per share fell 8.6% to 921.66 pence ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...